U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Core Insights - The U.S. FDA has approved TECVAYLI® in combination with DARZALEX FASPRO® for the treatment of adults with relapsed or refractory multiple myeloma, based on Phase 3 data showing significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard care [1][2] Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery technologies, including the ENHANZE® platform [1] - The company has commercialized ten products using ENHANZE® technology, impacting over one million patients globally [1] Product Approval Details - The approval of TECVAYLI® plus DARZALEX FASPRO® is based on the MajesTEC-3 study, which demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17 [1] - The three-year PFS rate for patients treated with the combination was reported at 83%, indicating a durable benefit [1] Technological Advancements - Halozyme's ENHANZE® technology facilitates subcutaneous delivery of drugs, reducing treatment burden and improving convenience for patients [1] - The company is expanding its drug delivery technology portfolio with Hypercon™ and Surf Bio's hyperconcentration technology, which aims to enhance the delivery of biologics [1] Financial Performance - Halozyme reported a record revenue of $1.4 billion for the full year 2025 and reiterated strong financial guidance for 2026 [2]